|
||
| |||||||
|
|
Paris, France – September 25, 2007 – Today DBV Technologies (DBV), a biopharmaceutical company engaged in the development of non-invasive epicutaneous delivery technology and products, and Numico announced an exclusive multi-annual promotion and distribution agreement for Diallertest® Milk, extending the original network, which covers France and certain overseas territories, to include the entire world. This partnership is part of the strategy of DBV Technologies to increase its international visibility. The French company DBV Technologies has developed a unique globally patented technology, VIASKIN®*, with the backing of ANVAR, for the cutaneous administration of proteins and peptides. In June 2004, DBV Technologies released the first ready-to-use patch test for the diagnosis of delayed allergy to cow’s milk proteins, which is based on this unique technology: Diallertest® Milk. Allergies are now a public health issue classified by WHO as the fourth global plague. In infants, cow’s milk protein allergy is the most frequently occurring and common food allergy. Causing a vast range of symptoms, this allergy is suffered painfully by children and their families alike since it is extremely difficult to diagnose. Diallertest® Milk was designed exclusively to diagnose cow’s milk protein allergy and is suitable for everyday medical practice. Practical, simple to use and painless, as it is completely non-invasive, and it can be applied directly by the parents to the child’s back at home. It significantly improves the efficacy in the diagnosis of cow’s milk protein allergy. The faster the diagnosis and treatment, the lower the risk of developing allergosis. Since February 2006, Nutricia France, a subsidiary of Numico, a Dutch multinational specializing in the production and sale of nutritional foodstuffs, has distributed Diallertest® Milk in France. At present, around 70,000 Diallertest® Milk tests have already been prescribed nationally as well as in various countries such as Mexico and in the Middle East region. Today, the new partnership with Numico will allow DBV Technologies to access a first-class international distribution network. For Numico, this agreement is part of its new global strategy known as “act against allergy”: one of the focuses of the group’s work is the earlier diagnosis of a cow’s milk protein allergy in order to limit the risk of development of allergosis and to offer relevant products to newborn. Thus Diallertest® Milk is an integral part of the development plans for Numico’s flagship product: Neocate®. “We are delighted to enter into this significant partnership with Numico (€2.6 billion of consolidated revenues in 2006). This partnership allows us to position our first diagnostic product at a global level thanks to the support of a group leader in its specialist field and to push forward the development program of our allergy diagnosis and treatment product range, Diallertest® Milk”, Jean-François Biry, CEO comments. “DiallertestÒ milk fits perfectly with our portfolio of products for cow’s milk allergy. Numico is unique in being the only company to offer the full range of products for the management of cow’s milk allergy. DiallertestÒ milk is the perfect diagnostic companion for these products and we are excited about the potential this product offers our business, Jonathan Wogel, GI / Allergy Business Unit Director comments. *This technology was awarded the Siemens Prize for Innovation 2006. - Ends - About DBV Technologies DBV Technologies, headquartered in Boulogne-Billancourt, near Paris, is a biopharmaceutical company specialising in the development of non-invasive epicutaneous diagnostics and immunotherapies for allergy diagnosis and treatment. The Company is headed by Jean-François Biry, Chairman & CEO and was born out of the experience of Doctor Pierre-Henri Benhamou, a paediatrician specialising in gastro-enterology, allergosis and nutrition, and Bertrand Dupont, a qualified engineer from the Arts et Métiers Institute. DBV’s lead product, Diallertest® Milk, is on sale in France and several other countries for the diagnosis of cow’s milk protein allergy. The product represents a revolution in paediatrics and was awarded an International prize for Technological Innovation by the Altran foundation. Founded in 2002, DBV Technologies has ca.30 employees and is based in the Pépinière Paris Santé Cochin, in Paris’ 14th arrondissement. More information can be found at www.dbv-technologies.com. For more information on cow’s milk protein allergy, visit http://allergieaulaitdevache.com and www.aplv-leblog.com About VIASKIN® The company has perfected and patented worldwide its VIASKIN® technology, a unique delivery system that retains the active compound on the carrier using electrostatic forces only. This allows active compounds to be delivered to the epidermis of the skin without breaking the blood-skin barrier. The Company has a pipeline of Diallertest® products geared for the diagnosis of other allergies including wheat, soya bean and dust mites. The VIASKIN® technology is in development for use in treating allergies through desensitisation and for the administration of vaccines. The company is currently seeking partnerships in these areas. The technology was awarded the Siemen’s prize for Innovation 2006. About Numico Royal Numico is a high-growth, high-margin specialised nutrition company with leading positions in Baby Food and Clinical Nutrition and brings products to the market under the brand names Nutricia, SHS, Milupa, Cow & Gate, Mellin and Dumex, among others. The company serves customers in over 100 countries and employs approx. 13,000 people and generated approximately €2.6 billion of consolidated revenues in 2006. Numico is acknowledged as the European and Asia Pacific market leader in infant nutrition and medical nutrition, our products range from infant milk formula to specialised nutrition for babies with specific needs and for breastfeeding mothers. For people with specific nutritional requirements, Numico offers a complete range of enteral clinical nutrition, diet products and disease-specific nutrition. www.numico.com / www.shsweb.co.uk / www.actagainstallergy.co.uk For further information please contact:
|
| ||||||||||||
| ||||||||
